Rosemann, Achim (2014) Why regenerative stem cell medicine progresses slower than expected. Journal of Cellular Biochemistry, 115 (12). pp. 2073-2076. ISSN 0730-2312
![]()
|
PDF
- Published Version
Available under License Creative Commons Attribution No Derivatives. Download (73kB) | Preview |
Abstract
Stem cell research has been acclaimed to revolutionize the future of medicine, and to offer new treatments for previously incurable diseases. Despite years of research, however, the therapeutic potential of stem cell research has not yet been fully realized. By June 2014, the US Food and Drug Administration had approved only five stem cell-based medicinal products, all of which cord blood derived hematopoietic stem cell products for the cure of blood and immunological diseases. Anticipated treatments for cancer, neurodegenerative disorders, gastroenterological, myocardial, and other diseases are still far from routine applications. What are the reasons for the slow progress in the stem cell field, and the mismatch between public expectations and actual achievements?
Item Type: | Article |
---|---|
Schools and Departments: | School of Global Studies > Anthropology |
Subjects: | H Social Sciences Q Science Q Science > QH Natural history > QH0301 Biology > QH0705 Economic biology Q Science > QH Natural history > QH0301 Biology R Medicine |
Depositing User: | Achim Rosemann |
Date Deposited: | 16 Oct 2014 08:39 |
Last Modified: | 07 Mar 2017 03:27 |
URI: | http://srodev.sussex.ac.uk/id/eprint/50588 |
View download statistics for this item
📧 Request an updateProject Name | Sussex Project Number | Funder | Funder Ref |
---|---|---|---|
Bionetworking in Asia - International collaboration, exchange, and responsible innovation in the life sciences | G0750 | ESRC-ECONOMIC & SOCIAL RESEARCH COUNCIL | ES/I018107/1 |